Erratum: Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter (Proceedings of the National Academy of Sciences of the United States of America (2011) 108, 9, (3785-3790) DOI: 10.1073/pnas.1011920108);Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 9, 2011, Pages 3785-3790

  Thompson, Brent J ^a,c   Jessen, Tammy ^a   Henry, L K ^a,d   Field, Julie R ^a   Gamble, Karen L ^a,e   Gresch, Paul J ^a   Carneiro, Ana M ^a   Horton, Rebecca E ^b   Chisnell, Peter J ^a   Belova, Yekaterina ^a   McMahon, Douglas G ^a   Daws, Lynette C ^b   Blakely, Randy D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF NORTH DAKOTA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; COCAINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ELECTROPHYSIOLOGY; GENE MUTATION; GENETIC TRANSFECTION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79952746509     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104147108     Document Type: Erratum

References (58)

1. Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355-366.
2. Esteve JM, Launay J-M, Kellermann O, Maroteaux L (2007) Functions of serotonin in hypoxic pulmonary vascular remodeling. Cell Biochem Biophys 47:33-44.
3. Hart CM, Block ER (1989) Lung serotonin metabolism. Clin Chest Med 10:59-70.
4. Nguyen TT, et al. (1999) Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance. Placenta 20:3-11. (Pubitemid 29039245)
5. Serretti A, Artioli P (2004) The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 4:233-244. (Pubitemid 39136766)
6. Wong ML, Licinio J (2001) Research and treatment approaches to depression. Nat Rev Neurosci 2:343-351.
7. Hamplová-Peichlová J, et al. (2002) Citalopram inhibits L-type calcium channel current in rat cardiomyocytes in culture. Physiol Res 51:317-321. (Pubitemid 34970188)
8. Tytgat J, Maertens C, Daenens P (1997) Effect of fluoxetine on a neuronal, voltage-dependent potassium channel (Kv1.1). Br J Pharmacol 122:1417-1424. (Pubitemid 27503933)
9. Carrasco JL, Sandner C (2005) Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 59:1428-1434. (Pubitemid 43922630)
10. Carneiro AMD, Blakely RD (2006) Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J Biol Chem 281:24769-24780. (Pubitemid 44274251)
11. Prasad HC, et al. (2005) Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci USA 102:11545-11550. (Pubitemid 41153856)
12. Steiner JA, et al. (2009) cGMP-dependent protein kinase Ialpha associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake. Mol Brain 2:26.
13. Zhu C-B, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD (2005) p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 280:15649-15658. (Pubitemid 40616683)
14. Zhu C-B, Hewlett WA, Francis SH, Corbin JD, Blakely RD (2004) Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. Eur J Pharmacol 504:1-6. (Pubitemid 39410716)
15. Beck CH (1995) Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatry Neurosci 20:25-32.
16. Di Benedetto M, D'Addario C, Candeletti S, Romualdi P (2007) Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors. Brain Res 1128:33-39. (Pubitemid 46048637)
17. Frechilla D, Otano A, Del Río J (1998) Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 22:787-802. (Pubitemid 28396344)
18. Keiser MJ, et al. (2009) Predicting new molecular targets for known drugs. Nature 462:175-181.
19. Murphy DL, Lesch K-P (2008) Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 9:85-96. (Pubitemid 351164876)
20. Kalueff AV, Olivier JD, Nonkes LJ, Homberg JR (2010) Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci Biobehav Rev 34:373-386.
21. Olivier JD, et al. (2008) A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 152:573-584.
22. Sora I, et al. (2001) Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci USA 98:5300-5305. (Pubitemid 32397123)
23. Sora I, et al. (1998) Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704. (Pubitemid 28293316)
24. Field JR, Henry LK, Blakely RD (2010) Transmembrane domain 6 of the human serotonin transporter contributes to an aqueously accessible binding pocket for serotonin and the psychostimulant 3,4-methylene dioxymethamphetamine. J Biol Chem 285:11270-11280.
25. Henry LK, Meiler J, Blakely RD (2007) Bound to be different: neurotransmitter transporters meet their bacterial cousins. Mol Interv 7:306-309.
26. Kaufmann KW, et al. (2009) Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Proteins 74:630-642.
27. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl - dependent neurotransmitter transporters. Nature 437:215-223. (Pubitemid 41294479)
28. Henry LK, et al. (2006) Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 281:2012-2023. (Pubitemid 43845789)
29. Gartside S, Umbers V, Hajos M (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115:1064-1070.
30. Stahl SM (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51:215-235.
31. Baganz NL, et al. (2008) Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci USA 105:18976-18981.
32. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238-245. (Pubitemid 34465544)
33. Lucki I, Singh A, Kreiss DS (1994) Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 18:85-95. (Pubitemid 24058927)
34. Barker EL, et al. (1998) High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 273:19459-19468. (Pubitemid 28366995)
35. Kuhar MJ, Ritz MC, Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
36. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223. (Pubitemid 17131228)
37. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1988) Cocaine self-administration appears to be mediated by dopamine uptake inhibition. Prog Neuropsychopharmacol Biol Psychiatry 12:233-239.
38. Hnasko TS, Sotak BN, Palmiter RD (2007) Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin. J Neurosci 27:12484-12488. (Pubitemid 350127797)
39. Rocha BA (2003) Stimulant and reinforcing effects of cocaine in monoamine transporter knockout mice. Eur J Pharmacol 479:107-115.
40. Rocha BA, et al. (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1:132-137.
41. Mateo Y, Budygin EA, John CE, Jones SR (2004) Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc Natl Acad Sci USA 101:372-377. (Pubitemid 38084257)
42. Chen R, et al. (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103:9333-9338. (Pubitemid 43902577)
43. Thomsen M, Han DD, Gu HH, Caine SB (2009) Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J Pharmacol Exp Ther 331:204-211.
44. Dulawa SC, Hen R (2005) Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29:771-783. (Pubitemid 40762599)
45. Dranovsky A, Hen R (2006) Hippocampal neurogenesis: Regulation by stress and antidepressants. Biol Psychiatry 59:1136-1143.
46. Jacobson LH, Cryan JF (2007) Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet 37:171-213. (Pubitemid 46150858)
47. Crowley JJ, Blendy JA, Lucki I (2005) Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) 183:257-264. (Pubitemid 41609278)
48. Lucki I, Dalvi A, Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315-322. (Pubitemid 32477289)
49. Cervo L, et al. (2005) Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression. J Neurosci 25:8165-8172. (Pubitemid 41292111)
50. Grillon C, Levenson J, Pine DS (2007) A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: A fear-potentiated startle study. Neuropsychopharmacology 32:225-231. (Pubitemid 44967801)
51. Pollack MH (2005) The pharmacotherapy of panic disorder. J Clin Psychiatry 66(suppl 4):23-27.
52. Ansah T-A, Ramamoorthy S, Montañez S, Daws LC, Blakely RD (2003) Calcium-dependent inhibition of synaptosomal serotonin transport by the alpha 2-adrenoceptor agonist 5-bromo-N-[4,5-dihydro-1H-imidazol-2-yl]-6- quinoxalinamine (UK14304). J Pharmacol Exp Ther 305:956-965. (Pubitemid 36617973)
53. Zhu C-B, et al. (2007) Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. J Pharmacol Exp Ther 322:332-340. (Pubitemid 46956381)
54. Nunemaker CS, DeFazio RA, Moenter SM (2003) A targeted extracellular approach for recording long-term firing patterns of excitable cells: a practical guide. Biol Proced Online 5:53-62. (Pubitemid 38097499)
55. Evans AK, et al. (2008) Evidence for serotonin synthesis-dependent regulation of in vitro neuronal firing rates in the midbrain raphe complex. Eur J Pharmacol 590:136-149.
56. Toney GM, Daws LC (2006) Juxtacellular labeling and chemical phenotyping of extracellularly recorded neurons in vivo. Methods Mol Biol 337:127-137.
57. Daws LC, et al. (2005) Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry. J Neurosci Methods 143:49-62. (Pubitemid 40348789)
58. Carneiro AM, et al. (2009) Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. Proc Natl Acad Sci USA 106:2047-2052.